BRPI0606247A2 - uso de oxicodona para tratamento da dor visceral - Google Patents

uso de oxicodona para tratamento da dor visceral

Info

Publication number
BRPI0606247A2
BRPI0606247A2 BRPI0606247-4A BRPI0606247A BRPI0606247A2 BR PI0606247 A2 BRPI0606247 A2 BR PI0606247A2 BR PI0606247 A BRPI0606247 A BR PI0606247A BR PI0606247 A2 BRPI0606247 A2 BR PI0606247A2
Authority
BR
Brazil
Prior art keywords
visceral pain
oxycodone
pain treatment
effectively treated
treatment
Prior art date
Application number
BRPI0606247-4A
Other languages
English (en)
Inventor
Asbjorn Mohr
Lars Arendt
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35871217&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0606247(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Publication of BRPI0606247A2 publication Critical patent/BRPI0606247A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Abstract

USO DE OXICODONA PARA TRATAMENTO DA DOR VISCERAL. é possível tratar eficazmente a dor visceral moderada a grave pela administração de analgésicos compreendendo o opióide oxicodona ou sais farmaceuticamente aceitáveis deste. A dor visceral e principalmente a dor visceral aguda (isto é, não crónica) podem ser eficazmente tratadas pela administração de oxicodona em uma dose menor que a dose correspondente de outros opióides, tais como a morfina.
BRPI0606247-4A 2005-01-18 2006-01-17 uso de oxicodona para tratamento da dor visceral BRPI0606247A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64549005P 2005-01-18 2005-01-18
PCT/EP2006/050252 WO2006077212A1 (en) 2005-01-18 2006-01-17 Use of oxycodone for treating visceral pain

Publications (1)

Publication Number Publication Date
BRPI0606247A2 true BRPI0606247A2 (pt) 2009-06-09

Family

ID=35871217

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0606247-4A BRPI0606247A2 (pt) 2005-01-18 2006-01-17 uso de oxicodona para tratamento da dor visceral

Country Status (32)

Country Link
US (2) US20080200493A1 (pt)
EP (1) EP1838318B1 (pt)
JP (1) JP5049139B2 (pt)
KR (10) KR20200128451A (pt)
CN (1) CN101106996B (pt)
AP (1) AP2249A (pt)
AR (1) AR052880A1 (pt)
AT (2) ATE446092T1 (pt)
AU (1) AU2006207498B2 (pt)
BR (1) BRPI0606247A2 (pt)
CA (1) CA2595043C (pt)
CY (1) CY1109660T1 (pt)
DE (2) DE602006009899D1 (pt)
DK (2) DK1838318T3 (pt)
EA (1) EA013544B1 (pt)
ES (1) ES2333901T3 (pt)
HK (1) HK1107933A1 (pt)
HR (1) HRP20090679T1 (pt)
IL (1) IL184530A (pt)
ME (1) ME01066B (pt)
MX (1) MX2007007207A (pt)
MY (1) MY144471A (pt)
NO (1) NO338968B1 (pt)
NZ (1) NZ555852A (pt)
PL (1) PL1838318T3 (pt)
PT (1) PT1838318E (pt)
RS (1) RS51069B (pt)
SI (1) SI1838318T1 (pt)
TW (1) TWI432196B (pt)
UA (1) UA85471C2 (pt)
WO (1) WO2006077212A1 (pt)
ZA (1) ZA200705231B (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP2008004467A0 (en) 2005-11-14 2008-06-30 Rinat Neurosciene Corp Antagonist antibodies directed against calcitonin generelated peptide anf methods using same
CA2687192C (en) 2007-06-04 2015-11-24 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
BRPI0907135B8 (pt) 2008-03-04 2021-05-25 Labrys Biologics Inc uso de um anticorpo antagonista anti-cgrp para a prevenção e/ou tratamento de dor de câncer crônica
EP2393484A1 (en) 2009-02-06 2011-12-14 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
AU2010265213B2 (en) 2009-06-24 2012-08-23 Egalet Ltd. Controlled release formulations
AU2010288194B2 (en) 2009-08-28 2013-08-29 Teva Pharmaceuticals International Gmbh Methods for treating visceral pain by administering antagonist antibodies directed against calcitonin gene-related peptide
DK2710039T3 (en) 2011-05-20 2019-04-01 Alderbio Holdings Llc ANTI-CGRP COMPOSITIONS AND APPLICATION THEREOF
SG194973A1 (en) 2011-05-20 2013-12-30 Alderbio Holdings Llc Use of anti-cgrp antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers
EP2709662B1 (en) 2011-05-20 2019-07-31 AlderBio Holdings LLC Use of anti-cgrp or anti-cgrp-r antibodies or antibody fragments to treat or prevent chronic and acute forms of diarrhea
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
MX2016012188A (es) 2014-03-21 2017-04-27 Teva Pharmaceuticals Int Gmbh Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos.
JP6937368B2 (ja) 2016-09-23 2021-09-22 テバ・ファーマシューティカルズ・インターナショナル・ゲー・エム・ベー・ハー 難治性片頭痛の治療方法
KR20210094513A (ko) 2018-11-19 2021-07-29 재즈 파마슈티칼즈 아일랜드 리미티드 알코올-내성 약물 제형
CR20210373A (es) 2019-01-08 2021-08-19 H Lundbeck As Tratamiento agudo y tratamiento rápido de la cefalea usando anticuerpos anti-cgrp

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5656295A (en) * 1991-11-27 1997-08-12 Euro-Celtique, S.A. Controlled release oxycodone compositions
US5958459A (en) * 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
NZ332039A (en) * 1996-03-25 2000-06-23 Lilly Co Eli Method for treating pain using olanzapine and NSAIDs
UA81224C2 (uk) * 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
US6992193B2 (en) * 2003-06-10 2006-01-31 Adolor Corporation Sulfonylamino phenylacetamide derivatives and methods of their use

Also Published As

Publication number Publication date
CY1109660T1 (el) 2014-08-13
JP5049139B2 (ja) 2012-10-17
KR20120089710A (ko) 2012-08-13
DK1838318T3 (da) 2010-01-04
JP2008526927A (ja) 2008-07-24
WO2006077212A1 (en) 2006-07-27
EP1838318A1 (en) 2007-10-03
KR20190135557A (ko) 2019-12-06
KR20210131450A (ko) 2021-11-02
TWI432196B (zh) 2014-04-01
KR20200128451A (ko) 2020-11-12
EA200701541A1 (ru) 2008-02-28
CN101106996A (zh) 2008-01-16
CA2595043C (en) 2013-11-19
CN101106996B (zh) 2013-10-23
NO20074174L (no) 2007-10-17
NZ555852A (en) 2010-01-29
KR20230170811A (ko) 2023-12-19
AU2006207498A1 (en) 2006-07-27
KR20220165797A (ko) 2022-12-15
ZA200705231B (en) 2008-06-25
AP2249A (en) 2011-07-18
AT9895U1 (de) 2008-05-15
ES2333901T3 (es) 2010-03-02
RS51069B (sr) 2010-10-31
KR20080106991A (ko) 2008-12-09
AP2007004057A0 (en) 2007-08-31
HK1107933A1 (en) 2008-04-25
UA85471C2 (ru) 2009-01-26
PT1838318E (pt) 2009-12-15
ATE446092T1 (de) 2009-11-15
US9271974B2 (en) 2016-03-01
EP1838318B1 (en) 2009-10-21
US20150190393A1 (en) 2015-07-09
DK200700207U1 (da) 2007-08-24
ME01066B (me) 2012-10-20
AU2006207498B2 (en) 2009-11-19
EA013544B1 (ru) 2010-06-30
MY144471A (en) 2011-09-30
IL184530A (en) 2015-01-29
KR20170021905A (ko) 2017-02-28
NO338968B1 (no) 2016-11-07
MX2007007207A (es) 2007-08-15
DE602006009899D1 (de) 2009-12-03
KR20070100368A (ko) 2007-10-10
DK200700207U3 (da) 2007-09-28
AR052880A1 (es) 2007-04-11
DE202006019887U1 (de) 2007-07-26
CA2595043A1 (en) 2006-07-27
SI1838318T1 (sl) 2010-02-26
IL184530A0 (en) 2007-10-31
TW200637554A (en) 2006-11-01
HRP20090679T1 (hr) 2010-01-31
PL1838318T3 (pl) 2010-03-31
KR20140091782A (ko) 2014-07-22
US20080200493A1 (en) 2008-08-21

Similar Documents

Publication Publication Date Title
BRPI0606247A2 (pt) uso de oxicodona para tratamento da dor visceral
AU2018256546A1 (en) Combination therapy with peptide epoxyketones
UA109781C2 (uk) Сигма-ліганди для потенціювання аналгетичного ефекту опіоїдів і опіатів при післяопераційному болю і для послаблення залежності від них
IL221795B (en) Use of a pharmaceutical preparation of methylnaltrexone or a salt thereof for the preparation of a medicine for the treatment of side effects of treatment with opiates
WO2003070191A3 (en) Tamper-resistant transdermal opioid delivery devices
MX2020008616A (es) Rocio de fentanilo sublingual.
MXPA05010819A (es) Uso de antagonistas de opioide perifericos, especialmente metilnaltrexona para tratar sindrome de intestino irritable.
HK1140141A1 (en) Combination therapies comprising a quinoxaline inhibitors of pi3k-alpha for use in the treatment of cancer
WO2008131057A3 (en) Sustained release formulations of opioid and nonopioid analgesics
BR112014006356A2 (pt) nova composição farmacêutica resistente ao abuso para o tratamento de dependência de opioide
EA200802412A1 (ru) Терапевтические комбинации для сопровождающихся болью медицинских состояний
BR0214481A (pt) Método e composição para potenciação de um analgésico opiáceo
AR092820A1 (es) Sistemas y metodos para tratar una respuesta farmacodinamica adversa inducida por opioides, unidad de dosis, kit
MX2009005798A (es) Recuperacion de apoplejia.
PL1858496T3 (pl) Poprzezskórny układ terapeutyczny do aplikowania środków przeciwbólowych
CY1110152T1 (el) Χρηση συνδυασμου μορφινης και τουλαχιστον ενος ανταγωνιστη φυσικου οπιοειδους στην αγωγη της εξαρτησης απο φυσικα οπιοειδη και στην προληψη της μη στοματικης καταχρησης φυσικων οπιοειδων σε εξαρτημενους απο φυσικα οπιοειδη
WO2011109743A3 (en) Synergistic effects of combinations of buprenorphine and opioids for the treatment of pain
NO20064645L (no) Kombinasjoner av deramiciclan og opioider som smertestillende midler
ATE380550T1 (de) Synergistische kombination eines opiatanalgetikums und eines nsaid
WO2014023869A3 (es) Aplicacion terapéutica de agentes inhibidores de cd44 frente a la leucemia linfoblástica aguda (all) humana
TH85791A (th) วิธีการรักษาความเจ็บปวดอวัยวะภายใน
WO2005037318A3 (en) Treatment of arthritic conditions, chronic inflammation or pain
TH85791B (th) วิธีการรักษาความเจ็บปวดอวัยวะภายใน
PL1817029T3 (pl) Pochodna izoksazolowa do łagodzenia bólu neuropatycznego

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: EURO-CELTIQUE S.A. (LU)

B65X Notification of requirement for priority examination of patent application
B65Z Priority examination of the patent application refused (request does not comply with dec. 132/06 of 20061117)
B65X Notification of requirement for priority examination of patent application
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B65Z Priority examination of the patent application refused (request does not comply with dec. 132/06 of 20061117)
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL